Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who Is The Best Minor League Player In The Drug Pricing Debate?

Executive Summary

Now that the Senate Finance Committee has unveiled its bill and House leadership has outlined its approach, less comprehensive drug pricing legislation is losing the limelight. But may of the the bills could still have a meaningful impact on pharma, and might even become law, if only because they would be an easier way for politicians to show they were doing something to address the issue. 

You may also be interested in...



Drug Pricing Policies Attached To Surprise Medical Billing Legislation

Strategy could improve chances of passage, offer politicians the opportunity to show the public they are doing something to address drug pricing.

California's Pay-For-Delay Law May Be Harsher Than FTC Regulation, Could Face Legal Challenge

Governor Newsom signs bill that presumes brand-generic patent settlements are anticompetitive; AAM says the law violates US Constitution by attempting to regulate transactions outside the state.

Biosimilars In US Drug Pricing Debate: Second Chance – Or Maybe Last Chance

Current drug pricing legislative effort offers the prospect of a substantial update to 2010 biosimilar law – substantial at least in the list of statutory changes, if not in the potential near term impact on the marketplace.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS140563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel